Free Trial
NASDAQ:AXDX

Accelerate Diagnostics Q4 2024 Earnings Report

Accelerate Diagnostics logo
$0.55 +0.01 (+1.69%)
Closing price 04/25/2025 03:51 PM Eastern
Extended Trading
$0.58 +0.02 (+4.15%)
As of 04/25/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Accelerate Diagnostics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Accelerate Diagnostics Revenue Results

Actual Revenue
$2.82 million
Expected Revenue
$3.00 million
Beat/Miss
Missed by -$184.00 thousand
YoY Revenue Growth
N/A

Accelerate Diagnostics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 21, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Accelerate Diagnostics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Thursday, May 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Accelerate Diagnostics Earnings Headlines

Accelerate Diagnostics CEO Retention Bonus Agreement
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Accelerate Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Accelerate Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accelerate Diagnostics and other key companies, straight to your email.

About Accelerate Diagnostics

Accelerate Diagnostics (NASDAQ:AXDX), an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

View Accelerate Diagnostics Profile

More Earnings Resources from MarketBeat